Manufacturer: Wyeth Pharmaceuticals, Inc (owned by Pfizer) Generic name: Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) Prevnar 13 Safet The manufacturer’s clinical trials involved either administering Prevnar 13 with other vaccines at the same time or dividing subjects into one Prevnar 13 group and one Prevnar control group. In the first case it is impossible to know which vaccine caused a certain adverse event, allowing manufacturers to claim there is no evidence that it was their vaccine. In the second case there is no true placebo group, as both groups receive similar vaccines. Prevnar 13 was deemed to have a similar safety profile to Prevnar. Serious adverse events were said to be rare and included bronchiolitis, gastroenteritis and pneumonia (all recorded at 0.9%). The 3 sudden infant deaths recorded were said to be at no higher a rate than in the wider population. The longest follow-up period for serious adverse reactions was 30 days.  The UK passive reporting system has recorded 21 deaths over 12 years possibly related to pneumococcal conjugate vaccines and the US system has recorded 1170 deaths over 13 years. Neither system tells us if the vaccine was really the cause but both also suffer from problems of under-reporting and the real figures could be much higher. The US fatality count is enormous whichever way one looks at it and should ring alarm bells. It constitutes a fifth of all deaths recorded on the VAERS database for all vaccines, ever. Prevnar 13 Efficacy The vaccine is designed to protect against 13 serotypes of the bacterium Streptococcus pneumonia, of which there are more than 90. It is not known what causes this common bacterium to become a pathogen. Prevnar 13 efficacy was tested by showing that it was non-inferior to its predecessor (Prevnar) in terms of immunogenicity….